

Draft Guidance on Olanzapine

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Olanzapine

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two way crossover *in-vivo*
Strength: 5 mg
Subjects: Normal healthy males and females, general population
Additional Comments:

-
2. Type of Study: Fed
Design: Single-dose, two way crossover *in-vivo*
Strength: 5 mg
Subjects: Normal healthy males and females, general population
Additional Comments:
-

Analytes to measure (in appropriate biological fluid): Olanzapine in plasma

Bioequivalence based on (90% CI): Olanzapine

Waiver request of in-vivo testing: 2.5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg based on (i) acceptable bioequivalence studies on the 5 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.